Actinogen Medical Announces Third Positive XanaMIA Trial Review
Key points
- Third positive recommendation from independent Data Monitoring Committee
- Trial to continue without amendment
- Topline results expected in November 2026
- Xanamem shows promising safety profile in Alzheimer's treatment
Full summary
Actinogen Medical Limited announced that the independent Data Monitoring Committee (DMC) for its XanaMIA phase 2b/3 trial has recommended continuing the trial without amendments. The DMC reviewed safety data from all 247 trial participants, concluding the trial should proceed as planned. Xanamem, Actinogen's lead compound, continues to demonstrate a promising safety profile in patients with mild to moderate Alzheimer's disease. Topline results from the trial are expected in November 2026.
Summary generated by a large language model. Please interpret with care.